hVIVO plc (LON:HVO - Get Free Report)'s stock price dropped 46.3% on Saturday . The stock traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.70 ($0.12). Approximately 83,062,000 shares were traded during mid-day trading, an increase of 2,325% from the average daily volume of 3,424,608 shares. The stock had previously closed at GBX 16.20 ($0.22).
Wall Street Analysts Forecast Growth
Separately, Shore Capital reissued a "buy" rating on shares of hVIVO in a research report on Friday.
View Our Latest Analysis on HVO
hVIVO Trading Up 23.0%
The stock has a 50 day simple moving average of GBX 16.08 and a 200-day simple moving average of GBX 17.93. The firm has a market capitalization of £75.71 million, a P/E ratio of 4.41 and a beta of 0.97. The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86.
hVIVO (LON:HVO - Get Free Report) last posted its quarterly earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. On average, equities research analysts forecast that hVIVO plc will post 1.5492958 EPS for the current fiscal year.
Insider Buying and Selling at hVIVO
In other hVIVO news, insider Yamin Mo' Khan sold 3,062,246 shares of the stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($705,204.31). 14.03% of the stock is currently owned by corporate insiders.
About hVIVO
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
See Also
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
